LONDON, April 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 29, 2025 at 8:30 a.m. Eastern Time to report its first quarter 2025 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon ...

Core Viewpoint - Kiniksa Pharmaceuticals International, plc will host a conference call on April 29, 2025, to discuss its first quarter 2025 financial results and recent portfolio execution [1]. Group 1: Conference Call Details - The conference call is scheduled for April 29, 2025, at 8:30 a.m. Eastern Time [1]. - A live webcast will be available on the company's website, and participants can register for telephone access [2]. - A replay of the event will be accessible on Kiniksa's website approximately 48 hours after the call [2]. Group 2: Company Overview - Kiniksa is a biopharmaceutical company focused on developing therapies for debilitating diseases, particularly in cardiovascular indications [3]. - The company aims to discover, acquire, develop, and commercialize novel therapies for diseases with unmet needs [3]. - Kiniksa's portfolio is based on strong biological rationale and validated mechanisms, offering potential for differentiation in the market [3].

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Kiniksa Pharmaceuticals, Ltd. (KNSA) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.Kiniksa Pharmaceuticals, Ltd. is one of 1003 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in ord ...

Core Viewpoint - Kiniksa Pharmaceuticals, Ltd. (KNSA) shows significant upside potential with a mean price target of $35.86, indicating a 64.8% increase from the current trading price of $21.76 [1] Price Targets and Analyst Consensus - The average price target consists of seven estimates ranging from $30 to $40, with a standard deviation of $4.18, suggesting a moderate agreement among analysts [2] - The lowest estimate indicates a potential increase of 37.9%, while the highest suggests an 83.8% upside [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement direction [8] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding KNSA's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [10] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 9.1%, with one estimate moving higher and no negative revisions [11] - KNSA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [12]

Group 1 - Kiniksa Pharmaceuticals, Ltd. (KNSA) shares have increased by 15.7% in the past four weeks, closing at $22.61, with a mean price target of $35.86 indicating a potential upside of 58.6% [1] - The average price targets from analysts range from $30 to $40, with a standard deviation of $4.18, suggesting a strong agreement among analysts regarding the stock's potential movement [2] - Analysts have shown a positive trend in earnings estimate revisions, with the Zacks Consensus Estimate for the current year increasing by 186.7% over the past month, indicating strong earnings prospects for KNSA [10][11] Group 2 - KNSA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, which supports the stock's potential upside [11] - While price targets can be misleading, the direction indicated by the consensus price target for KNSA appears to be a useful guide for potential price movement [12] - Analysts' growing optimism regarding KNSA's earnings, reflected in the upward revisions of EPS estimates, correlates strongly with expected near-term stock price movements [9]

Investors might want to bet on Kiniksa Pharmaceuticals, Ltd. (KNSA) , as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook.The upward trend in estimate revisions for this company reflects growing optimism of analysts on its earnings prospects, which should get reflected in its stock price. After all, empirical research shows a strong correlation ...

Kiniksa Pharmaceuticals, Ltd. (KNSA) shares soared 5.8% in the last trading session to close at $21.46. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 3.5% gain over the past four weeks.The sudden rise in the share price can be attributed to the positive investor expectations regarding the continued strong sales growth of Kiniksa’s only approved drug, Arcalyst (rilonacept). The drug was initially approved by the FDA in 2021 for ...

Kiniksa Pharmaceuticals, Ltd. (KNSA) closed the last trading session at $20.28, gaining 3.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $35.17 indicates a 73.4% upside potential.The mean estimate comprises six short-term price targets with a standard deviation of $4.12. While the lowest estimate of $30 indicates a 47.9% increase from the current price level, the most optimisti ...

(Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38492 Kiniksa Pharmaceuticals International, plc (Exact name of registrant as specified in its charter) England an ...

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) reported Q4 2024 results and provided a big strategic shift for its pipeline. I must say I did not expect much from Kiniksa this week as the company pre-announced Arcalyst net sales for the fourth quarter and full-year 2025 net sales guidance last month ahead of the JPMorgan Healthcare Conference. And yet, we saw the discontinuation of the phase 2b trial of abiprubart in Sjogren’s syndrome and the end of the mavrilimumab collaboration with MedImmune, ...